New Delhi, February 19 Zydus Lifesciences announced on Thursday that it has launched its first biosimilar, developed indigenously, for the treatment of visual impairment.
Anyra, the country's first biosimilar of Aflibercept 2 mg, is indicated for the treatment of visual impairment caused by various conditions, including diabetes.
With this launch, the company reaffirms its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India, the Gujarat-based drug firm said in a statement.
Currently, more than 100 million people in India are living with diabetes, making it one of the largest diabetic populations globally.
"We are committed to making advanced biologics accessible to patients who need them most. ANYRA is a transformative step for affordable retinal care in India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding patient access to critical therapies with advanced biologics," said Zydus Lifesciences MD Sharvil P Patel.
The company also said that it has signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer for Anyra.
Shares of the drug firm were trading marginally up at Rs 910.25 apiece on BSE.